Moderna’s pioneering COVID shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its ...

Sales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter in a dramatic ...

The drugmaker is optimistic about higher sales with new vaccines and a little help from AI in the coming years.

(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its second vaccine, meant to prevent a common ...

The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from the expected ...

There are two new COVID-19 variants circulating, posing a threat to a summer surge. Is your last vaccine dose still ...

Biotechnology titan Moderna – known for its Covid-19 vaccines – has joined forces with artificial intelligence heavyweight OpenAI to accelerate drug development, including using the technology to ...

Moderna Inc.’s stock fell 2.6% Friday, after the company said the Food and Drug Administration will not complete its review ...

Moderna (MRNA) stock falls even as the Q1 2024 financials were better than expected despite lower demand for its COVID-19 ...

Moderna shares fell in intraday trading Friday as it said the FDA has pushed back its RSV vaccine approval decision until the ...

Sanofi said it has reached a licensing deal to sell Novavax’s Covid shot as well as to try to combine the vaccine with Sanofi’s own flu vaccine.